Suscribirse

The relation between managed care market share and the treatment of elderly fee-for-service patients with myocardial infarction - 02/09/11

Doi : 10.1016/S0002-9343(01)01098-1 
Paul A Heidenreich, MD a, b, d, , Mark McClellan, MD, PhD d, Craig Frances, MD e, Laurence C Baker, PhD c
a Veterans Affairs Palo Alto Health Care System (PAH), Palo Alto, California, USA 
b Department of Medicine (PAH), Stanford University, Palo Alto, California, USA 
c Department of Health Research and Policy (LCB), Stanford University, Palo Alto, California, USA 
d Department of Economics (PAH, MM), Stanford University, Palo Alto, California, USA 
e Veterans Affairs San Francisco Medical Center (CF), San Francisco, California, USA 

*Requests for reprints should be addressed to Paul A. Heidenreich, MD, Palo Alto VA Medical Center, 111C Cardiology, 3801 Miranda Avenue, Palo Alto, California 94304, USA.

Abstract

Purpose

To determine if greater managed care market share is associated with greater use of recommended therapies for fee-for-service patients with acute myocardial infarction.

Subjects and methods

We examined the care of 112 900 fee-for-service Medicare beneficiaries aged ≥65 years who resided in one of 320 metropolitan statistical areas and who were admitted with an acute myocardial infarction between February 1994 through July 1995. Use of recommended medical treatments and 30-day survival were determined for areas with low (<10%), medium (10% to 30%), and high (>30%) managed care market share.

Results

After adjustment for severity of illness, teaching status of the admission hospital, and area characteristics, areas with high levels of managed care had greater use of beta-blockers (relative risk [RR] for greater use = 1.18; 95% confidence interval [CI]: 1.06 to 1.29) and aspirin at discharge (RR = 1.05; 95% CI: 1.02 to 1.07), but less appropriate coronary angiography (RR = 0.93; 95% CI: 0.86 to 1.01) and reperfusion (RR = 0.95; 95% CI: 0.85 to 1.03) when compared with areas with low levels of managed care.

Conclusions

Medicare beneficiaries with fee-for-service insurance who resided in areas with high managed care activity were more likely to have received appropriate treatment with beta-blockers and aspirin, and less likely to have undergone coronary angiography following admission for myocardial infarction. Thus, the effects of managed care may not be limited to managed care enrollees.

El texto completo de este artículo está disponible en PDF.

Keywords : myocardial infarction, elderly, aspirin, beta-adrenergic blockers, coronary angiography, health maintenance organizations


Esquema


 Dr. Heidenreich is supported by a Career Development Award from the Veterans Affairs Health Services Research and Development Service.


© 2001  Excerpta Medica Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 112 - N° 3

P. 176-182 - février 2002 Regresar al número
Artículo precedente Artículo precedente
  • Potential cost savings of erythropoietin administration in end-stage renal disease
  • Denise M Hynes, Kevin T Stroupe, Joel W Greer, Domenic J Reda, Diane L Frankenfield, James S Kaufman, William G Henderson, William F Owen, Michael V Rocco, Jay B Wish, Jeffery Kang, John R Feussner
| Artículo siguiente Artículo siguiente
  • Clinical presentation of genetically defined patients with hypokalemic salt-losing tubulopathies
  • Melanie Peters, Nikola Jeck, Stephan Reinalter, Andreas Leonhardt, Burkhard Tönshoff, G.ünter Klaus, Martin Konrad, Hannsjörg W Seyberth

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.